Loading...

OmniAb, Inc.

OABINASDAQ
Healthcare
Biotechnology
$1.48
$-0.07(-4.52%)
U.S. Market opens in 1h 58m

OmniAb, Inc. Fundamental Analysis

OmniAb, Inc. (OABI) shows weak financial fundamentals with a PE ratio of -2.91, profit margin of -3.47%, and ROE of -23.99%. The company generates $0.0B in annual revenue with weak year-over-year growth of -29.27%.

Key Strengths

Cash Position28.57%
PEG Ratio-1.69
Current Ratio4.02

Areas of Concern

ROE-23.99%
Operating Margin-3.69%
We analyze OABI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -284.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-284.7/100

We analyze OABI's fundamental strength across five key dimensions:

Efficiency Score

Weak

OABI struggles to generate sufficient returns from assets.

ROA > 10%
-21.53%

Valuation Score

Excellent

OABI trades at attractive valuation levels.

PE < 25
-2.91
PEG Ratio < 2
-1.69

Growth Score

Weak

OABI faces weak or negative growth trends.

Revenue Growth > 5%
-29.27%
EPS Growth > 10%
6.56%

Financial Health Score

Excellent

OABI maintains a strong and stable balance sheet.

Debt/Equity < 1
0.08
Current Ratio > 1
4.02

Profitability Score

Weak

OABI struggles to sustain strong margins.

ROE > 15%
-2399.11%
Net Margin ≥ 15%
-3.47%
Positive Free Cash Flow
No

Key Financial Metrics

Is OABI Expensive or Cheap?

P/E Ratio

OABI trades at -2.91 times earnings. This suggests potential undervaluation.

-2.91

PEG Ratio

When adjusting for growth, OABI's PEG of -1.69 indicates potential undervaluation.

-1.69

Price to Book

The market values OmniAb, Inc. at 0.71 times its book value. This may indicate undervaluation.

0.71

EV/EBITDA

Enterprise value stands at -3.66 times EBITDA. This is generally considered low.

-3.66

How Well Does OABI Make Money?

Net Profit Margin

For every $100 in sales, OmniAb, Inc. keeps $-3.47 as profit after all expenses.

-3.47%

Operating Margin

Core operations generate -3.69 in profit for every $100 in revenue, before interest and taxes.

-3.69%

ROE

Management delivers $-23.99 in profit for every $100 of shareholder equity.

-23.99%

ROA

OmniAb, Inc. generates $-21.53 in profit for every $100 in assets, demonstrating efficient asset deployment.

-21.53%

Following the Money - Real Cash Generation

Operating Cash Flow

OmniAb, Inc. generates limited operating cash flow of $-32.47M, signaling weaker underlying cash strength.

$-32.47M

Free Cash Flow

OmniAb, Inc. generates weak or negative free cash flow of $-32.97M, restricting financial flexibility.

$-32.97M

FCF Per Share

Each share generates $-0.29 in free cash annually.

$-0.29

FCF Yield

OABI converts -22.13% of its market value into free cash.

-22.13%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.91

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.69

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.71

vs 25 benchmark

P/S Ratio

Price to sales ratio

8.99

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.08

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.02

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.24

vs 25 benchmark

ROA

Return on assets percentage

-0.22

vs 25 benchmark

ROCE

Return on capital employed

-0.24

vs 25 benchmark

How OABI Stacks Against Its Sector Peers

MetricOABI ValueSector AveragePerformance
P/E Ratio-2.9129.17 Better (Cheaper)
ROE-23.99%701.00% Weak
Net Margin-347.04%-43676.00% (disorted) Weak
Debt/Equity0.080.34 Strong (Low Leverage)
Current Ratio4.024.45 Strong Liquidity
ROA-21.53%-18965.00% (disorted) Weak

OABI outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews OmniAb, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-18.94%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-272.81%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-1117.83%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ